Back to top
more

Roche Holding AG (RHHBY)

(Delayed Data from OTC)

$41.30 USD

41.30
968,736

-0.81 (-1.92%)

Updated Oct 21, 2020 02:43 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (169 out of 254)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Zacks Equity Research

Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

Zacks Equity Research

AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review

AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.

Zacks Equity Research

Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales

Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.

Zacks Equity Research

Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

Zacks Equity Research

Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC

The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.

Zacks Equity Research

Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod

Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).

Zacks Equity Research

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.

Kinjel Shah

Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates

J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.

Zacks Equity Research

Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval

Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.

Zacks Equity Research

Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study

Bayer's (BAYRY) Aliqopa combined with Rituxan met the primary endpoint of significantly prolonging PFS in a phase III study in patients with relapsed indolent non-Hodgkin's lymphoma.

Zacks Equity Research

Roche's (RHHBY) 9M20 Sales Affected by COVID-19 Outbreak

Roche's (RHHBY) performance in the first nine months gets negatively impacted by coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

Zacks Equity Research

Regeneron Gains on EUA Request for Coronavirus Treatment

Regeneron's (REGN) stock up following the submission of a request to the FDA for granting an Emergency Use Authorization to its experimental COVID-19 treatment, REGN-COV2.

Zacks Equity Research

Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC

Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.

Sheraz Mian

Top Stock Reports for Adobe, Costco & Union Pacific

Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Costco Wholesale (COST) and Union Pacific (UNP).

Zacks Equity Research

Bristol Myers' Opdivo & Yervoy Win FDA Nod for Mesothelioma

Bristol Myers' (BMY) Opdivo in combination with Yervoy gets an FDA approval for malignant pleural mesothelioma.

Zacks Equity Research

Regeneron, Gilead in Focus as Trump Tests COVID-19 Positive

The biotech companies experimenting coronavirus treatments are in greater focus now as President Trump test COVID-19 positive.

Zacks Equity Research

Ionis' Alexander Disease Candidate Gets Orphan Drug Status

The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.

Kinjel Shah

Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs

New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.

Zacks Equity Research

Regeneron Surges on Coronavirus Treatment Development Efforts

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.

Zacks Equity Research

Regeneron's Coronavirus Antibody Cocktail Study Data Promising

Regeneron (REGN) announces encouraging initial data from its seamless phase I/II/III study, evaluating antibody cocktail candidate, REGN-COV2, in non-hospitalized patients with COVID-19.

Zacks Equity Research

Infinity's Eganelisib Gets Fast Track Tag for Breast Cancer

Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line setting.

Zacks Equity Research

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.

Zacks Equity Research

Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH

Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.

Zacks Equity Research

Bristol-Myers' Opdivo Meets Goals in Bladder Cancer Study

Bristol-Myers' (BMY) Opdivo meets primary endpoint in a phase III study in patients with urothelial carcinoma.

Zacks Equity Research

AC Immune's Candidate Fails in Alzheimer's Disease Study

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.